Lantheus To Acquire Progenics Pharma In All-Stock Deal

Micro-cap biotech Progenics Pharmaceuticals, Inc. PGNX is advancing strongly following an announcement concerning a buyout deal.

The Deal

Lantheus Holdings Inc LNTH and Progenics, which uses artificial intelligence to find, fight and follow cancer, announced an agreement under which the former will acquire the latter in an all-stock deal.

The agreement provides for Progenics shareholders receiving 0.2502 shares of Lantheus for each Progenics share they hold.

This exchange ratio, according to the release, values Progenics at a 35% premium to its 30-day volume-weighted average closing price, and a 21% premium to the closing price on Tuesday.

Lantheus is the parent company of Lantheus Medical Imaging, which manufactures diagnostic imaging agents and products.

The boards of both companies have approved the transaction.

The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data

Deal Logic

The combination of Lantheus and Progenics will form a company with a diversified diagnostic and therapeutics portfolio, the companies said in the release.

The two companies had pro forma combined revenues of $370.1 million for the 12-month period ended June 30, 2019.

The deal is premised on the logic of leveraging Lantheus' expertise in complex manufacturing, supply chain and commercial excellence, with Progenics' three leading FDA approved products, clinical pipeline and development capabilities.

"This combination unlocks additional value for stakeholders and stockholders alike through Lantheus' enhanced resources and R&D capabilities, proven commercial expertise and complementary portfolio of products," said Mark Baker, CEO of Progenics.

The deal is expected to close in the first quarter of 2020, subject to approval by Lantheus and Progenics stockholders, regulatory approvals, and customary closing conditions

Price Action

Progenics shares were up 9.80% to $5.44, while Lantheus shares were slipping 21.66% to $18.82.

Posted In: BiotechM&ANewsContractsTrading Ideas

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.